LONCOR 300- florfenicol injection, solution
Elanco US Inc.
For intramuscular and subcutaneous use in beef and non-lactating dairy cattle only
Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
LONCOR™ 300 Injectable Solution is a solution of the synthetic antibiotic florfenicol. Each milliliter of sterile LONCOR™ 300 contains 300 mg of florfenicol, 250 mg N-Methyl-2-pyrrolidone, 150 mg propylene glycol, and polyethylene glycol qs.
LONCOR™ 300 is indicated for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica , Pasteurella multocida , and Histophilus somni , and for the treatment of bovine interdigital phlegmon (foot rot, acute interdigital necrobacillosis, infectious pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus. Also, it is indicated for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica , Pasteurella multocida , and Histophilus somni.
For treatment of bovine respiratory disease (BRD) and bovine interdigital phlegmon (foot rot): LONCOR™ 300 should be administered by intramuscular injection to cattle at a dose rate of 20 mg/kg body weight (3 mL/100 lbs). A second dose should be administered 48 hours later. Alternatively, LONCOR™ 300 can be administered by a single subcutaneous (SC) injection to cattle at a dose rate of 40 mg/kg body weight (6 mL/100 lbs). Do not administer more than 10 mL at each site. The injection should be given only in the neck.
NOTE: Intramuscular injection may result in local tissue reaction which persists beyond 28 days. This may result in trim loss of edible tissue at slaughter. Tissue reaction at injection sites other than the neck is likely to be more severe.
For control of respiratory disease in cattle at high risk of developing BRD: LONCOR™ 300 should be administered by a single subcutaneous injection to cattle at a dose rate of 40 mg/kg body weight (6 mL/100 lbs). Do not administer more than 10 mL at each site. The injection should be given only in the neck.
|ANIMALWEIGHT (lbs)||IMLONCOR 300 DOSAGE3.0 mL/100 lb Body Weight(mL)||SC LONCOR 300DOSAGE6.0 mL/100 lbBody Weight (mL)|
Clinical improvement should be evident in most treated subjects within 24 hours of initiation of treatment. If a positive response is not noted within 72 hours of initiation of treatment, the diagnosis should be re-evaluated.
|Do not inject more than 10 mL per injection site.|
Do not use in animals that have shown hypersensitivity to florfenicol.
NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN.
This product contains materials that can be irritating to skin and eyes. Avoid direct contact with skin, eyes, and clothing. In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. Consult a physician if irritation persists. Accidental injection of this product may cause local irritation. Consult a physician immediately. The Safety Data Sheet (SDS) contains more detailed occupational safety information. For customer service, adverse effects reporting, and/or a copy of the SDS, call 1-800-422-9874.
Not for use in animals intended for breeding purposes. The effects of florfenicol on bovine reproductive performance, pregnancy, and lactation have not been determined. Toxicity studies in dogs, rats, and mice have associated the use of florfenicol with testicular degeneration and atrophy. Intramuscular injection may result in local tissue reaction which persists beyond 28 days. This may result in trim loss of edible tissue at slaughter. Tissue reaction at injection sites other than the neck is likely to be more severe.
Animals intended for human consumption must not be slaughtered within 28 days of the last intramuscular treatment. Animals intended for human consumption must not be slaughtered within 38 days of subcutaneous treatment. This product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or calves born to these cows. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.
Inappetence, decreased water consumption, or diarrhea may occur transiently following treatment.
To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Elanco at 1-800-422-9874. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.
The pharmacokinetic disposition of florfenicol was evaluated in feeder calves following single intramuscular (IM) administration at the recommended dose of 20 mg/kg body weight. Florfenicol was also administered intravenously (IV) to the same cattle in order to calculate the volume of distribution, clearance, and percent bioavailability1 (Table 1).
* harmonic mean
** mean value
*** following IV administration
Cmax Maximum serum concentration
Tmax Time at which Cmax is observed
T 1/2 Biological half-life
AUC Area under the curve
Vdss Volume of distribution at steady state
Clt Total body clearance
|Cmax (μg/mL)||3.07*||1.43 — 5.60|
|Tmax (hr)||3.33||0.75 — 8.00|
|T 1/2 (hr)||18.3**||8.30 — 44.0|
|AUC (μg•min/mL)||4242||3200 — 6250|
|Bioavailability (%)||78.5||59.3 — 106|
|Vdss (L/kg)***||0.77||0.68 — 0.85|
|Clt (mL/min/kg)***||3.75||3.17 — 4.31|
Florfenicol was detectable in the serum of most animals through 60 hours after intramuscular administration with a mean concentration of 0.19 μg/mL. The protein binding of florfenicol was 12.7%, 13.2%, and 18.3% at serum concentrations of 0.5, 3.0, and 16.0 μg/mL, respectively.
VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.